Sanomab Ltd Press releases
1 - 1 of 1 Press Release
May 11, 2012
Sanomab annouces an exclusive evaluation license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody. Sanomab will develop the novel human therapeutic antibody for use in the treatment of pancreatic cancer.